Developments Awakn screens first patient in Phase 3 trial of treatment for AUD Awakn Life Sciences (CSE:AWKN; OTCQB:AWKNF; FSE:954) has announced that the first patient has been screened in its landmark MORE-KARE Phase 3 trial of AWKN-001, an investigational, novel medication-assisted treatment... August 9, 2024